[PDF][PDF] Hematology, TransfusionandCellTherapy
RS Tavares, A Nonino, KBB Pagnano… - SciELO Brasil
Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia,
Hemoterapia e Terapia Cellular: Project guidel Page 1 hematol transfus cell ther. 2019;41(S1):1–73 …
Hemoterapia e Terapia Cellular: Project guidel Page 1 hematol transfus cell ther. 2019;41(S1):1–73 …
Risikoadaptierte Therapie chronischer BCR-ABL1-negativer MPN
FH Heidel, K Döhner - InFo Hämatologie+ Onkologie, 2019 - Springer
Zu den chronischen BCR-ABL1-negativen myeloproliferativen Neoplasien (MPN) gehören
die Entitäten Polycythaemia vera (PV), essenzielle Thrombozythämie (ET) und die primäre …
die Entitäten Polycythaemia vera (PV), essenzielle Thrombozythämie (ET) und die primäre …
Reducing the burden of MPN
MF McMullin - Blood, The Journal of the American Society of …, 2019 - ashpublications.org
In the MPNs polycythemia vera (PV) and essential thrombocythemia (ET), the acquired
clone causes excess production of hemopoietic cells. This results in a spectrum of disease …
clone causes excess production of hemopoietic cells. This results in a spectrum of disease …
[PDF][PDF] Achtergronden bij de richtlijn Essentiële trombocytemie 2019
PAW te Boekhorst, S Kersting, NPM Schaap… - 2019 - ariez.nl
Recentelijk zijn de richtlijnen voor de diagnostiek en behandeling van de
myeloproliferatieve neoplasieën (MPN) essentiële trombocytemie (ET), polycythemia vera …
myeloproliferatieve neoplasieën (MPN) essentiële trombocytemie (ET), polycythemia vera …
[PDF][PDF] Ruxolitinib in the treatment of patients with myelofibrosis—questions and answers
K Warzocha, W Homenda, A Pluta… - Oncology in Clinical …, 2019 - journals.viamedica.pl
Myelofibrosis (MF) is a clonal disease, arising as a result of somatic mutations in pluripotent
stem cells. This leads to proliferation of atypical megakaryocytes and disfunction of the bone …
stem cells. This leads to proliferation of atypical megakaryocytes and disfunction of the bone …
Risk-adapted treatment of chronic BCR-ABL1 negative myeloproliferative neoplasms
FH Heidel, K Döhner - Der Onkologe, 2019 - Springer
Hintergrund Zu den klassischen chronischen BCR-ABL1-negativen myeloproliferativen
Neoplasien (MPN) zählen die drei großen Entitäten Polycythaemia vera (PV), essenzielle …
Neoplasien (MPN) zählen die drei großen Entitäten Polycythaemia vera (PV), essenzielle …
[PDF][PDF] Management of essential thrombocythemia
RA Mesa, CN Harrison - Fast Facts: Myeloproliferative Neoplasms, 2019 - karger.com
As described in Chapter 3, the risk of thrombosis in ET is assessed on the basis of age and
previous history of thrombosis. 1 Thus, a patient below the age of 60 years with no previous …
previous history of thrombosis. 1 Thus, a patient below the age of 60 years with no previous …
Effets régulateurs du ruxolitinib sur l'expression de marqueurs de l'inflammation et de protéines de détoxication des médicaments
M Febvre-James - 2019 - theses.hal.science
Le ruxolitinib, un inhibiteur de JAK1/2, est actuellement utilisé pour le traitement des
syndromes myéloprolifératifs et montre des propriétés anti-inflammatoires. Cependant, les …
syndromes myéloprolifératifs et montre des propriétés anti-inflammatoires. Cependant, les …